产品
编 号：F753099
分子式：C23H18F3N5O3S
分子量：501.48
分子式：C23H18F3N5O3S
分子量：501.48
产品类型
规格
价格
是否有货
结构图
CAS No: 2474977-38-1
产品详情
生物活性：
COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 μM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.
体内研究：
COX-2/sEH-IN-1 (Compound 9c) (10 mg/kg; p.o.; once) exhibits analgesic activity.COX-2/sEH-IN-1 (50 mg/kg; p.o.; once) shows high anti-inflammatory activity.COX-2/sEH-IN-1 (100 mg/kg; p.o.; 2 weeks) affords a perfect cardio-protection and less cardiovascular liabilities.Animal Model:Albino mice (20-30 g)
Dosage:10 mg/kg
Administration:Oral administration, once
Result:Exhibited analgesic activity with 65.67% inhibition in the number of writhing.
Animal Model:Albino rats (120-150 g), carrageenan-induced paw edema model
Dosage:50 mg/kg
Administration:Oral administration, once
Result:Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively.
Animal Model:Adult male albino Wister rats (170-200 g)
Dosage:100 mg/kg
Administration:Oral administration, 2 weeks
Result:Exhibited a significant lowering in Troponine-I, LDH and CK-MB levels when compared to celecoxib treated group. Showed remarkably decrease in TNF-α concentration compared to the celecoxib induced cardio-toxicity group. Restored heart GSH level and significantly increased PGI2 level compared to celecoxib group. Showed mild decongestant and mild edema on cardiac blood vessels and showed more or less normal muscle bundles.
COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 μM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.
体内研究：
COX-2/sEH-IN-1 (Compound 9c) (10 mg/kg; p.o.; once) exhibits analgesic activity.COX-2/sEH-IN-1 (50 mg/kg; p.o.; once) shows high anti-inflammatory activity.COX-2/sEH-IN-1 (100 mg/kg; p.o.; 2 weeks) affords a perfect cardio-protection and less cardiovascular liabilities.Animal Model:Albino mice (20-30 g)
Dosage:10 mg/kg
Administration:Oral administration, once
Result:Exhibited analgesic activity with 65.67% inhibition in the number of writhing.
Animal Model:Albino rats (120-150 g), carrageenan-induced paw edema model
Dosage:50 mg/kg
Administration:Oral administration, once
Result:Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively.
Animal Model:Adult male albino Wister rats (170-200 g)
Dosage:100 mg/kg
Administration:Oral administration, 2 weeks
Result:Exhibited a significant lowering in Troponine-I, LDH and CK-MB levels when compared to celecoxib treated group. Showed remarkably decrease in TNF-α concentration compared to the celecoxib induced cardio-toxicity group. Restored heart GSH level and significantly increased PGI2 level compared to celecoxib group. Showed mild decongestant and mild edema on cardiac blood vessels and showed more or less normal muscle bundles.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备